Table 4 Pharmacokinetic parameters for pazopanib and lapatinib on day 15 of cycle 1

From: Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

Dose level   Pazopanib Lapatinib
Paclitaxel (mg m2) Pazopanib (mg) Lapatinib (mg) n AUC(0–24)(μ g* hr ml−1) Cmax(μ g ml−1) AUC(0–24)(μ g*hr ml−1) Cmax(μ g ml−1)
50 400 1000 6a 633 (279, 1436) 31.7 (14.6, 68.8) 20.0 (8.90, 44.8) 1.27 (0.531, 3.02)
50 800 1000 3b 960 (736, 1620) 48.9 (40.7, 80.9) 51.4 (42.3, 71.4) 3.67 (3.38, 5.46)
80 800 1000 1c 1027 57.4 11.6 0.95
80 400 1000 9a 646 (432, 967) 32 (21.9, 46.9) 27.1 (16.7, 43.8) 1.95 (1.13, 3.37)
  1. Abbreviations: AUC(0–24)=area under the concentration–time curve from time 0–24 h; Cmax=maximum observed concentration.
  2. aData are reported as geometric mean (95% confidence interval).
  3. bData are reported as median (range).
  4. cIndividual data values are provided.